🇺🇸 FDA
Patent

US 12186406

Materials and methods for treatment of hereditary haemochromatosis

granted A61KA61K48/005A61K48/0058

Quick answer

US patent 12186406 (Materials and methods for treatment of hereditary haemochromatosis) held by CRISPR THERAPEUTICS AG expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K48/005, A61K48/0058, A61K48/0066, A61K48/0075